2026
conference-abstract
OpenAlex
Ingrid A. Franken, Suzanna J. Schraa, Steven L. C. Ketelaars, Carmen Rubio‐Alarcón et autres
Abstract Introduction: Patients with stage II colon cancer (CC) not classified as high risk do not receive adjuvant chemotherapy (ACT) according to Dutch guidelines. However, 15-20% of patients with stage II CC experience disease recurrence, highlighting an unmet clinical need to identify …
nl, us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Ingrid Franken, Suzanna Schraa, Karlijn van Rooijen, Dave van der Kruijssen et autres
Abstract Introduction: Patients with stage II colon cancer not classified as high risk (pT4 microsatellite stable) do not receive adjuvant chemotherapy (ACT) according to Dutch guidelines. However, 15-20% of these patients experience a disease recurrence, indicating the unmet clinical need to identify …
nl, us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Ingrid A. Franken, Suzanna J. Schraa, Karlijn van Rooijen, Dave van der Kruijssen et autres
Abstract Introduction: Patients with stage II colon cancer not classified as high risk (pT4 microsatellite stable) do not receive adjuvant chemotherapy (ACT) according to Dutch guidelines. However, 15-20% of patients with stage II colon cancer experience a disease recurrence, indicating that there …
nl, us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Carmen Rubio‐Alarcón, Steven L. C. Ketelaars, Ingrid A. Franken, Sietske C. van Nassau et autres
Abstract Introduction: Surgery followed by adjuvant chemotherapy (ACT) is standard of care in stage III colon cancer. However, 50% of the patients would be cured by surgery alone and are being overtreated, while 30-35% will experience a recurrence despite adjuvant treatment, resulting …
nl, us
(code pays fourni par la source)